Literature DB >> 19479722

New pieces in the puzzle: how does interferon-beta really work in multiple sclerosis?

Meike Mitsdoerffer, Vijay Kuchroo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19479722     DOI： 10.1002/ana.21722

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  12 in total

1.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

2.  Cytosolic RIG-I-like helicases act as negative regulators of sterile inflammation in the CNS.

Authors:  Angela Dann; Hendrik Poeck; Andrew L Croxford; Stefanie Gaupp; Katrin Kierdorf; Markus Knust; Dietmar Pfeifer; Cornelius Maihoefer; Stefan Endres; Ulrich Kalinke; Sven G Meuth; Heinz Wiendl; Klaus-Peter Knobeloch; Shizuo Akira; Ari Waisman; Gunther Hartmann; Marco Prinz
Journal:  Nat Neurosci       Date:  2011-12-04       Impact factor: 24.884

Review 3.  The immunology of multiple sclerosis.

Authors:  Kathrine E Attfield; Lise Torp Jensen; Max Kaufmann; Manuel A Friese; Lars Fugger
Journal:  Nat Rev Immunol       Date:  2022-05-04       Impact factor: 53.106

Review 4.  Role and therapeutic value of dendritic cells in central nervous system autoimmunity.

Authors:  F J Quintana; A Yeste; I D Mascanfroni
Journal:  Cell Death Differ       Date:  2014-08-29       Impact factor: 15.828

5.  Selective depletion of CD11c+ CD11b+ dendritic cells partially abrogates tolerogenic effects of intravenous MOG in murine EAE.

Authors:  Limei Wang; Zichen Li; Bogoljub Ciric; Farinaz Safavi; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Eur J Immunol       Date:  2016-10       Impact factor: 5.532

6.  Interleukin 17F level and interferon β response in patients with multiple sclerosis.

Authors:  Hans-Peter Hartung; Lawrence Steinman; Douglas S Goodin; Giancarlo Comi; Stuart Cook; Massimo Filippi; Paul O'Connor; Douglas R Jeffery; Ludwig Kappos; Robert Axtell; Volker Knappertz; Timon Bogumil; Susanne Schwenke; Ed Croze; Rupert Sandbrink; Christopher Pohl
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

Review 7.  [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].

Authors:  H-P Hartung; J Haas; M Meergans; F Tracik; S Ortler
Journal:  Nervenarzt       Date:  2013-06       Impact factor: 1.214

8.  Interferon-β induces hepatocyte growth factor in monocytes of multiple sclerosis patients.

Authors:  Nicolas Molnarfi; Mahdia Benkhoucha; Kristbjörg Bjarnadóttir; Catherine Juillard; Patrice H Lalive
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

9.  Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor.

Authors:  Veit Rothhammer; Ivan D Mascanfroni; Lukas Bunse; Maisa C Takenaka; Jessica E Kenison; Lior Mayo; Chun-Cheih Chao; Bonny Patel; Raymond Yan; Manon Blain; Jorge I Alvarez; Hania Kébir; Niroshana Anandasabapathy; Guillermo Izquierdo; Steffen Jung; Nikolaus Obholzer; Nathalie Pochet; Clary B Clish; Marco Prinz; Alexandre Prat; Jack Antel; Francisco J Quintana
Journal:  Nat Med       Date:  2016-05-09       Impact factor: 53.440

Review 10.  Multiple Sclerosis: Immunopathology and Treatment Update.

Authors:  Narges Dargahi; Maria Katsara; Theodore Tselios; Maria-Eleni Androutsou; Maximilian de Courten; John Matsoukas; Vasso Apostolopoulos
Journal:  Brain Sci       Date:  2017-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.